Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05841355 · ClinicalTrials.gov registry record · NA

MADRE (Mammograms Available Due to Research and Education)

A NA study of Breast Cancer Screening, sponsored by University of Illinois at Chicago.

Recruiting
Registry status
NA
Development phase
600
Enrollment target
2
Study locations

NCT05841355: Recruiting NA study of Breast Cancer Screening, sponsored by University of Illinois at Chicago.

NCT05841355 is a NA study of Breast Cancer Screening that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 600 participants, below the 63,367-participant average among 8 other Breast Cancer Screening trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05841355, a NA study of Breast Cancer Screening, is actively recruiting participants, sponsored by University of Illinois at Chicago.

RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
2
Study locations

Study Summary

The design builds on past studies by integrating social network analysis (SNA) and implementation science (IS) into a longitudinal randomized clinical trial (RCT). The investigator will compare the long-term effects of interventions by examining guideline-concordant initial and repeat Breast Cancer (BC) screening.

Primary Outcome

Compare the number of participants in the empowerment arm that obtain guideline-concordant initial and repeat BC screening with the the number of participants in the education arm

Conditions Studied

Interventions

  • OTHER Educate
  • OTHER Empower

Study Locations (2)

Illinois

  • Mile Square Health Center - Chicago
  • University of Illinois Health - Chicago

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2023-03-14
Est. Completion 2027-08-31
Phase NA
University of Illinois at Chicago

430 total trials

What NCT05841355 shows while recruiting

NCT05841355 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 63,367-participant average among 8 other Breast Cancer Screening trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Breast Cancer Screening appearing as the primary indexed condition, and to 2 interventions - of which Educate is the first listed.

NCT05841355 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05841355 about?

NCT05841355 is a clinical study titled "MADRE (Mammograms Available Due to Research and Education)". The design builds on past studies by integrating social network analysis (SNA) and implementation science (IS) into a longitudinal randomized clinical trial (RCT). The investigator will compare the long-term effects of interventions by examining guideline-concordant initial and repeat Breast Cancer ...

What is the current status of trial NCT05841355?

This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2023-03-14. Estimated completion is 2027-08-31.

What conditions does trial NCT05841355 study?

This clinical trial studies the following conditions: Breast Cancer Screening.

What interventions are being tested in trial NCT05841355?

The interventions under investigation include: Educate (OTHER), Empower (OTHER).

Who is sponsoring clinical trial NCT05841355?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05841355 being conducted?

This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Screening

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05841355's enrollment target sits among peer trials

600 6th of 8 higher than 3 of 8 other Breast Cancer Screening trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer Screening trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05841355, the US trial registry maintained by the National Library of Medicine. NCT05841355 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.